Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:NVO).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVO, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 22 uncommon options trades for Novo Nordisk.
This isn't normal.
The overall sentiment of these big-money traders is split between 45% bullish and 31%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $216,312, and 17 are calls, for a total amount of $1,024,460.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $115.0 to $175.0 for Novo Nordisk over the recent three months.
Volume & Open Interest Trends
In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 1509.47 with a total volume of 1,139.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Novo Nordisk's big money trades within a strike price range of $115.0 to $175.0 over the last 30 days.
Novo Nordisk Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
NVO | CALL | SWEEP | NEUTRAL | 03/21/25 | $12.15 | $12.15 | $12.15 | $155.00 | $172.4K | 81 | 0 |
NVO | CALL | TRADE | NEUTRAL | 01/16/26 | $23.7 | $22.9 | $23.25 | $150.00 | $160.4K | 1.7K | 27 |
NVO | CALL | TRADE | BEARISH | 09/20/24 | $3.05 | $2.82 | $2.89 | $160.00 | $101.1K | 7.0K | 201 |
NVO | CALL | TRADE | BEARISH | 01/16/26 | $23.35 | $23.0 | $23.0 | $150.00 | $80.5K | 1.7K | 99 |
NVO | CALL | TRADE | BEARISH | 01/16/26 | $23.65 | $23.25 | $23.25 | $150.00 | $58.1K | 1.7K | 2 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Novo Nordisk's Current Market Status
Currently trading with a volume of 2,226,468, the NVO's price is down by -0.87%, now at $142.02.
RSI readings suggest the stock is currently may be approaching overbought.
Anticipated earnings release is in 56 days.
What The Experts Say On Novo Nordisk
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $160.0.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.
持有大量現金的投資者採取了看好的態度，對諾和諾德（紐交所：NVO）持股。
零售交易者應該知道。
我們在這裏追蹤的公開期權歷史記錄上看到交易時發現了這一點。
無論這些機構是真的還是隻是富人，我們都不知道。但當一些大事發生在NVO，通常意味着有人知道即將發生的事情。
那麼我們如何知道這些投資者剛剛做了什麼呢？
今天，Benzinga的期權掃描器發現了22筆諾和諾德不尋常的期權交易。
這不正常。
這些大手交易者的情緒總體上分爲45%的看漲和31%的看跌。
在我們發現的所有特殊期權中，有5個是看跌期權，金額總計爲216,312美元，而有17個是看漲期權，金額總計爲1,024,460美元。
預計價格目標
根據交易活動，看起來重要的投資者正在尋求在最近三個月內，將諾和諾德的價格區間從115.0美元到175.0美元。
成交量和未平倉量趨勢
就流動性和興趣而言，今天諾和諾德期權交易的平均持倉量爲1509.47，總成交量爲1,139.00。
在下面的圖表中，我們可以跟蹤過去30天內，諾和諾德大筆交易的看漲和看跌期權的成交量和持倉量的發展，這些交易的行權價格區間是115.0美元至175.0美元。
Novo Nordisk過去30天的期權成交量和未平倉合約
最大的期權交易：
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
NVO | CALL | SWEEP | NEUTRAL | 03/21/25 | $12.15 | $12.15 | $12.15 | $155.00 | $172.4K | 81 | 0 |
NVO | CALL | TRADE | NEUTRAL | 01/16/26 | $23.7 | $22.9 | $23.25 | $150.00 | $160.4K | 1.7K | 27 |
NVO | CALL | TRADE | BEARISH | 09/20/24 | $3.05 | $2.82 | $2.89 | $160.00 | $101.1K | 7.0K | 201 |
NVO | CALL | TRADE | BEARISH | 01/16/26 | $23.35 | $23.0 | $23.0 | $150.00 | $80.5K | 1.7K | 99 |
NVO | CALL | TRADE | BEARISH | 01/16/26 | $23.65 | $23.25 | $23.25 | $150.00 | $58.1K | 1.7K | 2 |
諾和諾德是一家領先的全球醫療保健公司，致力於研發創新藥品，幫助患糖尿病的患者過上更長壽、更健康的生活，這一傳統已有100多年。這種傳統爲我們提供了經驗和能力，使我們能夠推動變革，幫助人們戰勝其他嚴重的慢性疾病，如肥胖症、罕見的血液和內分泌紊亂。我們始終堅信，持久的成功公式是保持專注，長遠思考，並以財務、社會和環境負責任的方式做生意。諾和諾德在新澤西州設有美國總部，在7個州加上華盛頓特區擁有商業、生產和研究設施，在全國約有8000名員工。有關更多信息，訪問novonordisk-us.com，Facebook、Instagram和X。
作爲全球治療糖尿病品牌市場三分之一的領先者，丹麥的Novo Nordisk公司是世界上提供糖尿病護理產品的主要製造商和市場推廣者。該公司製造和銷售各種人體和現代胰島素、GLP-1療法等可注射糖尿病治療藥物、口服降糖藥以及肥胖症治療藥物。Novo Nordisk還有一個生物製藥部門（約佔營收的10%），專門從事血友病和其他疾病的蛋白質療法。
在審查了諾和諾德的期權交易模式之後，我們現在將注意力直接轉向公司。這種轉變使我們能夠深入探討其當前的市場位置和表現。
諾和諾德的當前市場狀態
專家對諾和諾德的評價
在過去30天中，共有1名專業分析師發表了對該股票的看法，設定了160.0美元的平均目標價格。
期權交易具有更高的風險和潛在回報。精明的交易者通過不斷教育自己、調整策略、監控多種因子和密切關注市場動態來管理這些風險。通過Benzinga Pro實時警報了解最新的Novo Nordisk期權交易情況。
